A clinical trial of the effects and safety of ra76 cream on remission maintenance of atopic dermatitis.

A clinical trial of the effects and safety of ra76 cream on remission maintenance of atopic dermatitis. - A clinical trial of the effects and safety of ra76 cream on remission maintenance of atopic dermatitis.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025722

Enrollment

Registered

2017-01-20

Start date

2017-01-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

Washout for 1week -&gt

Applying a topical steroid twice a day for 2 weeks -&gt

Applying ra76 cream twice a day for 4 weeks (In case of disease progression, it is allowed to apply a topical steroid in combination under the assessment of the principal investigator) Washout for 1we

Applying active comparator twice a day for 4 weeks (In case of disease progression, it is allowed to apply a topical steroid in combination under the assessment of the principal investigator)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Patients with atopic dermatitis. 2) Patients with mild or moderate rash on test site (both arms). 3) Patients who use moisturizer on body including both arms.

Exclusion criteria

Exclusion criteria: 1) Patients with severe skin disorders on test site (both arms) and deemed inappropriate to participate in this study by the principal investigator or sub-investigators. 2) Patients with any complications which affect the results of this study. 3) Patients who might use any external use medicines, anti-allergy drugs, or immunosuppressants. 4) Patients with a past history of allergy with test drug components. 5) Patients with hemorrhagic disease. 6) Patients with risk of serious disease in an injury. 7) Patients with menopausal trouble or on menopausal hormone therapy 8) Pregnant or lactating patients. Patients with suspicion of pregnancy. 9) Patients deemed inappropriate to participate in this study by the principal investigator or sub-investigators.

Design outcomes

Primary

Measure	Time frame
The period of the remission maintenance of atopic dermatitis in ra76 cream or active comparator applying term.	—

Secondary

Measure	Time frame
1) Severity classification (simple method) of atopic dermatitis developed by the advisory committee of atopic dermatitis severity classification of Japanese Dermatological Association at test site (both arms). 2) Transepidermal water loss, water content of the stratum corneum, erythema and pigmentation, and skin surface topography at test site (both arms), etc. 3) Questionnaires for QOL assessment in atopic dermatitis.	—

Measure

Time frame

1) Severity classification (simple method) of atopic dermatitis developed by the advisory committee of atopic dermatitis severity classification of Japanese Dermatological Association at test site (both arms). 2) Transepidermal water loss, water content of the stratum corneum, erythema and pigmentation, and skin surface topography at test site (both arms), etc. 3) Questionnaires for QOL assessment in atopic dermatitis.

—

Countries

Japan

Contacts

Public ContactYukiyoshi Katsumata

Exam CO.,LTD DermaLabo

katsumata-y@ekusamu.co.jp011-205-0781

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026